A prospective randomized trial of povidone-iodine suppository before transrectal ultrasonography-guided prostate biopsy

Hoyoung Ryu, MD\textsuperscript{a}, Sang Hun Song, MD\textsuperscript{a}, Sang Eun Lee, MD, PhD\textsuperscript{a}, Kyoung-Ho Song, MD, PhD\textsuperscript{b}, Sangchul Lee, MD, PhD\textsuperscript{a,\textasteriskcentered}\textsuperscript{a}

Abstract

Objectives: To investigate a way to reduce infectious complication after transrectal ultrasonography-guided prostate biopsy (TRUS-Bx), we planned a randomized trial to determine whether the use of the povidone-iodine suppository is effective in preventing infectious complications.

Methods: This study prospectively evaluated 250 patients who underwent TRUS-Bx during December 2014 and May 2016. Clinical questionnaire responses and safety were evaluated. Povidone-iodine suppository after glycerin enema was performed 1 to 2 hours before TRUS-Bx. Both groups received the prophylactic antibiotics (ceftriaxone 2.0 g) 30 to 60 minutes before TRUS-Bx. No antibiotics were prescribed after TRUS-Bx.

Results: The 120 were assigned in the treatment group using povidone-iodine suppository and 130 were assigned in the control group. There was no significant difference of clinicopathologic features including age, prostate-specific antigen and cancer detection rate in both groups ($P > .05$). No infectious and non-infectious complications were reported in both groups. Povidone-iodine suppository-related side effects were not reported. No significant differences in international prostate symptom score, sexual health inventory for men score, and European Organization for Research and Treatment of Cancer Quality of Life questionnaire scores were found between the 2 groups ($P > .05$). No changes in each questionnaire scores between before and after TRUS-Bx were observed.

Conclusions: Despite satisfying the predefined sample size, we could not prove the hypothesis that the use of povidone-iodine suppositories after TRUS-Bx would reduce infectious complications. A large-scale, multicenter, prospective study is needed to fully evaluate the clinical efficacy and safety of povidone-iodine suppository prior to TRUS-Bx.

Abbreviations: EORTX-QLQ-C30 = the European organization for research and treatment of cancer quality of life, IPSS = International Prostate Symptom Score, LUTS = lower urinary tract symptom, PSA = prostate-specific antigen, SHIM = sexual health inventory for men, TRUS = transrectal ultrasonography, TRUS-Bx = transrectal ultrasonography prostate biopsy.

Keywords: antibiotics, complication, povidone-iodine suppository, prospective randomized trial, prostate biopsy

1. Introduction

The number of prostate cancer cases is rapidly increasing among men; thus, the number of transrectal prostate biopsies for diagnosing prostate cancer is also rapidly increasing. As active surveillance for patients with low Gleason scores and prostate-specific antigen (PSA) levels shows an increasing trend, the incidence of transrectal prostate biopsy is expanding even more. In the decision-making process of men potentially facing a prostate biopsy, simple, noninvasive, objective parameters should be used, alone or in combination with prostate volume and, nevertheless, it is necessary to refer to nomograms in order to increase the accuracy of the biopsy.\cite{1,2} Moreover, increasing role of biomarkers and multi-parametric magnetic resonance imaging (mpMRI) led to reduction of unnecessary biopsy and potential reclassification biopsy in active surveillance with prostate biopsy.\cite{13,15} This effort is important to reduce unnecessary testing because prostate biopsy is an invasive procedure and can lead to fatal consequences. In this sense, prevention of subsequent complications after transrectal ultrasonography-guided prostate biopsy (TRUS-Bx) became more important. Other studies have reported that infectious and non-infectious complications occurred (hematuria, urinary retention, etc.) in approximately 5% to 10% of patients after TRUS-Bx.\cite{6} Infectious complications such as febrile urinary tract infections
were observed in 4.2% to 5.1% of patients, requiring hospitalization in 81% to 100% of these patients, and in some cases, a severe clinical course such as sepsis may be observed. Several attempts have been reported to reduce infectious complications after TRUS-Bx, including the use of antibiotics. We found that the use of rectal cleansing with povidone-iodine before TRUS-Bx could reduce the incidence of post-TRUS-Bx complications such as infection. Some studies reported that bowel preparation could reduce the incidence of infectious complications before TRUS-Bx. However, some studies reported opposite results. Few retrospective studies and a small-sized prospective study reported that rectal cleansing with povidone-iodine could reduce the incidence of infectious complications during TRUS-Bx. However, these studies had the limitations of a small number of patients, selection bias, and retrospective nature. No prospective study has been conducted to clarify the effect of povidone-iodine suppository before TRUS-Bx.

Povidone-iodine is widely used as a disinfectant for the prevention and treatment of wound infections, and the safety and usefulness of povidone-iodine suppositories especially in the field of gynecology have already been widely accepted. Therefore, we investigated the prophylactic effect of povidone-iodine as a safe and proven-effective suppository before TRUS-Bx.

2. Materials and methods

We planned a prospective randomized trial of 276 patients who would be candidates for TRUS-Bx and were recruited from December 2014 to May 2016 at our institution. The patients were randomly assigned to the groups at a ratio of 1:1 by clinical research coordinator. Of these patients, 26 patients were excluded owing to withdrawal from the trial (n = 6) and not performing prostate biopsy (n = 20). Finally, 250 patients were enrolled. To maintain the allocation concealment, the randomization table was placed in a sealed envelope, checked by a third party, and opened just before the patient was assigned. The patients were assigned to the treatment and control groups on the day of prostate biopsy. Before the procedure, the patients were divided into 2 groups, a treatment group (n = 120) with povidone-iodine suppository and a control group (n = 130) without suppository. Urinalysis, urine culture, and stool culture (rectal swab), demographic data (age, height, weight, and body mass index), complete blood count (CBC), admission panel, erythrocyte sedimentation rate (ESR), C reactive protein (CRP) level, and thyroid function test were performed before TRUS-Bx. In addition, by using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ-C30), International Prostate Symptom Score (IPSS) questionnaire, and Sexual Health Inventory for Men (SHIM) questionnaire, we evaluated the stability of the povidone-iodine suppository and the patient’s symptoms before and after the procedure (Fig. 1).

All the patients received an intravenous injection of 2-g ceftriaxone 30 minutes to 1 hour before TRUS-Bx, and no additional antibiotic prescription was given thereafter. Before prostate biopsy, glycerin enema was performed to both groups approximately 3 hours before the biopsy. In the treatment group, 200 mg of povidone-iodine suppository was inserted 1 to 2 hours before the procedure. All transrectal prostate biopsies were performed as 12-core biopsies using an 18-gauge punch needle. Additional biopsy was performed up to a maximum of 4 cores if hypoechoic lesions were identified. One experienced radiologic expert performed the procedure to maintain the consistency of the TRUS-Bx.

The participants returned home without complications such as fever and bleeding after TRUS-Bx. No antibiotics were prescribed after TRUS-Bx. After TRUS-Bx, the body temperature from the eardrum was measured and recorded it twice before the first follow-up visit. The patients were interviewed for febrile complications and complications of the povidone iodine suppositories at the first follow-up visit and reevaluated using the questionnaires (SHIM, Social Sciences 22.0 software (SPSS Inc., Chicago, II.), IPSS total, IPSS QoL) before the TRUS-Bx.

The primary end point of this study was defined as the incidence of infectious complications such as fever and urinary tract infection within 1 to 2 weeks after TRUS-Bx. Infectious complication was defined as a tympanic membrane temperature ≥38°C within 3 days of prostate biopsy or as the case of visiting a medical institution for treatment due to high-fever symptoms. The exclusion criteria were hypersensitivity to povidone-iodine, thyroid dysfunction, renal failure, dermatitis, and radioiodine treatment.

According to the Cochrane Collaboration report that analyzed previously reported literature by meta-analysis, the incidence rates of infectious complications were 10% for fever, 14% for bacteriuria, 9% for urinary tract infection, and 18% for bacteremia. Overall, infectious complications occurred in approximately 12.7% of the patients in the control group without antibiotics after prostate biopsy. The use of povidone-iodine prior to biopsy showed an approximately 80% reduction in complication rates (hazard ratio, 0.23; 90% confidence interval, 0.10–0.54) based on the meta-analysis reported by Pu et al. Therefore, 2.5% of infectious complications occurred in the povidone-iodine-treated group. When calculating the allocation ratio per group by 1:1 with 80% power (β value, 1–0.8 = 0.2) and 5% type 1 error (α value; false positive; 2-sided), 120 candidates were required in each group. Considering a dropout rate of 15%, 276 subjects were prospectively recruited.

To determine the clinical usefulness of povidone-iodine suppositories, we analyzed the incidence of infectious complications using cross tabulation and the chi-square test in comparison with those in the control group. A logistic regression univariate analysis was designed to analyze whether the administration of povidone-iodine suppository would be an independent predictor of the occurrence of infectious complications. Statistical analysis was performed on a per-protocol analysis basis, using the Statistical Package for the Social Sciences 22.0 software (SPSS Inc., Chicago, II.). A P value of <.05 was considered statistically significant. All these studies were conducted with institutional review board approval (IRB No. B-1403/243-004).

3. Results

In the treatment and control groups, the mean ages were 66.6 ± 8.6 and 65.2 ± 9.1 years; PSA levels, 12.6 ± 1.8 and 11.6 ± 3.2 ng/mL; number of biopsy cores, 12.9 ± 1.1 and 13.0 ± 1.2; and mean prostate volume, 42.4 ± 19.9 and 40.5 ± 17.2 mL, respectively (Table 1). The cancer detection rates (treatment group: 33.3% vs control group: 28.5%, P = .100) and the number of biopsy cores (treatment group: 12.9 ± 1.1 vs control group: 13.0 ± 1.2, P = .139) were not significantly different between the groups. The level of pre-biopsy CRP in both groups were 0.20 ± 0.54 and 0.19 ± 0.37 mg/dL, respectively (Table 1). Of the 250 patients, 74 (29.6%) patients were diagnosed with prostate cancer, (Gleason group 1–21 patients; group 2–25 patients; group 3–11 patients; group 4–15 patients; group 5–4 patients). Definition of Gleason group was based on International Society for Urological Pathology (ISUP) 2014 amendment.
Infectious complications did not occur in both groups, as well as any non-infectious complications such as bleeding and severe pain. Povidone-iodine suppository-related side effects were not reported in this study. No significant differences in IPSS, SHIM, and EORTC QLQ-C30 scores were found between the 2 groups (P > .05).

To examine povidone-iodine suppository-related side effects, we compared changes in questionnaire scores of the patient and control groups between pre-biopsy and post-biopsy (Table 3). The thyroid function test result after TRUS-Bx was within the normal range in both groups. Figure 2 shows the changes in questionnaire responses in both groups from before to after TRUS-Bx. The SHIM score of the treatment group was relatively higher than that of the control group and the post-biopsy decrease was relatively greater in the control group. The IPSS total and IPSS QoL scores were lower in the treatment group than in the control group and the post-biopsy score was higher in the control group than in the treatment group. The EORTC QLQ-C30 scores showed no significant change in both groups from

---

**Table 1**

Pre-biopsy characteristics of the total patients.

|                          | Treatment group (n = 120) | Control group (n = 130) |
|--------------------------|--------------------------|------------------------|
| Age, years               | 66.6 ± 8.6               | 65.2 ± 9.1             |
| BMI (kg/m²)              | 42.2 ± 18.0              | 41.4 ± 16.6            |
| Pre-biopsy PSA level (ng/mL) | 12.6 ± 1.8               | 11.6 ± 5.2             |
| Prostate volume (mL)     | 42.4 ± 19.9              | 40.5 ± 17.2            |
| Cancer detection rates (%) | 33.3                    | 28.5                   |
| Number of biopsy cores   | 12.9 ± 1.1               | 13.0 ± 1.2             |
| Complications            |                          |                        |
| Infection                | 0                        | 0                      |
| Bleeding                 | 0                        | 0                      |
| Severe pain              | 0                        | 0                      |
| Other                    | 0                        | 0                      |
| Questionnaire scores     |                          |                        |
| SHIM                     | 11.4 ± 7.8               | 11.2 ± 7.8             |
| EORTC QLQ-C30            | 45.1 ± 6.5               | 46.5 ± 8.0             |
| IPSS Total               | 10.0 ± 6.8               | 11.0 ± 7.0             |
| IPSS: QoL                | 2.3 ± 1.5                | 2.5 ± 1.4              |
| Nocturna                 | 1.7 ± 0.9                | 1.7 ± 1.1              |

EORTC QLQ-C30 = the European organization for research and treatment of cancer quality of life, IPSS = International Prostate Symptom Score, SHIM = sexual health inventory for men.
rates. As for the iodine suppositories reduce vaginitis and postoperative infection Bx unlike in our study. Among the previous studies of suppository povidone-iodine solutions were used immediately prior to TRUS-Bx. However, these studies were limited owing to their retrospective design and small consortium.\cite{23,24} We investigated the incidence of infection-related complications after TRUS-Bx. In a meta-analysis reported by Pu et al, the incidence rates of cephalosporins in this study. As a result, the absence of infectious complications in all 250 patients in the treatment and control groups in this study accounts for the superior prophylactic effect of third-generation cephalosporins.

On the basis of these reports, we also used third-generation cephalosporins in this study. As a result, the absence of infectious complications in all 250 patients in the treatment and control groups in this study accounts for the superior prophylactic effect of third-generation cephalosporins.

As noted earlier, no infectious complication from using povidone-iodine suppositories was observed in both the treatment and control groups in this study. The 2 common prophylactic procedures applied in both groups were third-generation cephalosporin antibiotics and glycerin enema, in which the former is shown to be the more decisive factor in preventing infectious complications. In the study performed by Chung et al, the incidence rates of fluoroquinolone-resistant and extended-spectrum beta-lactamase production were 48.1% and 11.8%, respectively.\cite{26} Recent reports also indicated that targeted antibiotic prophylaxis with rectal-culture screening may have significant benefits.\cite{27} However, performing targeted rectal swab cultures has obvious difficulties depending on regions and institutions, making it clinically inevitable to use empirical antibiotics. In this regard, the present study proved that third-generation cephalosporin is an effective empirical prophylactic antibiotic that can be used prior to TRUS-Bx. However, since there was no control group that did not use third-generation cephalosporins, this study could not ultimately demonstrate that

Table 2

Post-biopsy questionnaire scores of the 2 groups.

| Questionnaire scores | Treatment group (n = 120) | Control group (n = 130) | P Value | 95% confidential interval(CI) |
|----------------------|--------------------------|------------------------|---------|-----------------------------|
| SHIM                 | 11.2 ± 7.8               | 10.28 ± 7.68           | .490    | 0.958–1.021 |
| EORTC QLQ-C30       | 45.1 ± 6.0               | 46.44 ± 6.25           | .164    | 0.900–1.062 |
| IPSS Total           | 10.0 ± 6.8               | 11.7 ± 7.0             | .206    | 0.987–1.062 |
| IPSS: QOL            | 2.2 ± 1.5                | 2.7 ± 1.4              | .168    | 0.951–1.337 |
| Nocturia             | 1.4 ± 1.0                | 1.6 ± 1.1              | .119    | 0.611–1.106 |

\(EORTC\) QLQ-C30 = the European organization for research and treatment of cancer quality of life, IPSS = International Prostate Symptom Score, SHIM = sexual health inventory for men.

Table 3

The change of questionnaire scores between pre- and post-biopsy setting.

| Questionnaire scores change | Treatment group (n = 120) | Control group (n = 130) | P Value | 95% confidential interval(CI) |
|-----------------------------|--------------------------|------------------------|---------|-----------------------------|
| SHIM                        | −0.5 ± 4.0               | −1.0 ± 3.7             | .302    | −0.451–1.459                |
| EORTC QLQ-C30              | −0.1 ± 5.3               | −0.1 ± 4.9             | .936    | −1.322–1.219                |
| IPSS Total                  | −0.1 ± 4.8               | 0.8 ± 3.9              | .176    | −1.830–0.332                |
| IPSS: QOL                   | −0.1 ± 0.9               | 0.1 ± 0.8              | .375    | −0.451–1.459                |
| Nocturia                    | −0.4 ± 0.8               | −0.3 ± 0.7             | .036    | 0.080–0.700                 |

\(EORTC\) QLQ-C30 = the European organization for research and treatment of cancer quality of life, IPSS = International Prostate Symptom Score, SHIM = sexual health inventory for men.
third-generation cephalosporins are efficient at preventing post-TRUS-Bx infectious complications.

Aside from the fact that rectal preparation decreases the amount of feces in the rectum, thereby producing a superior acoustic window for prostate imaging, numerous studies have demonstrated that rectal preparation reduces the risk of infectious complications.\textsuperscript{[12,26]} However, the point at which to begin rectal preparations is still unremarkable.\textsuperscript{[30]} Some institutions perform enema 1 day prior to TRUS-Bx and restrict oral intake on the day of biopsy. In this study, we performed glycerin enema 4 hours prior to biopsy and restricted oral intake after the morning meal on the day of biopsy. As dietary restriction and bowel preparation prior to procedures are crucial to patient discomfort, while this study did not prove that bowel preparation alone can prevent infectious complications, it does demonstrate that with the proper antibiotic, minimal rectal preparation can be as effective with the least amount of discomfort to the patient in the process.

We surveyed patient discomfort and subjective complications between groups but found no statistically significant differences. When the average questionnaires scores were compared between the 2 groups, the statistical average scores for LUTS in the povidone-iodine suppository groups showed improvement as compared with those in the control groups. No previous studies have demonstrated that povidone-iodine can alleviate LUTS, and we deduced that the results were due to the placebo effect in the treatment group, assuming that the patients in the group were being provided better care with the additional use of suppositories. However, this also suggests that the suppository type does not increase patient discomfort as compared with the control. As previous cleansing with povidone-iodine has been reported to increase distress and irritation, this study demonstrates that the application of suppository types is effective in significantly lessening patient discomfort.\textsuperscript{[15]}

Our study has limitations. First, it was conducted without a double-blinded method, thus the possibility of the patients in the treatment group to be under the impression of being provided better care with the povidone-iodine suppository than the control group, confounding the results of the survey. Second, the use of third-generation cephalosporins inadvertently interfered with the identification of the efficacy of povidone-iodine suppositories in infectious complications. As mentioned earlier, previous studies have mostly used fluoroquinolone as prophylaxis, and a research...
on the efficacy of suppositories in patients with fluoroquinolone-resistant pathogens may have had more statistical significance. Other limitations include the selection bias of the homogeneity of the subjects chosen from a single institution, while antibiotic resistance is reported to be highly variable between regions. The limited number of enrolled patients also does not allow for sufficient analysis of patient discomfort and side effects due to suppository application. This is in part due to the primary intention of the study design to identify the statistical efficacy of povidone-iodine suppositories between the 2 groups, rather than the efficacy of the suppository itself. However, no evidence shows that povidone-iodine suppositories cause discomfort and irritation when applied in the rectum, and this study showed that the quality of life post TRUS-Bx was not affected by the use of the rectal medium.

Pre-biopsy rectal cleansing using povidone-iodine suppositories could not be demonstrated to reduce the rate of infectious complications because there was no infectious event despite our study satisfying the predefined sample size. A large-scale, multicenter, prospective study is needed to fully evaluate the clinical efficacy and safety of povidone-iodine suppository prior to TRUS-Bx.

Author contributions

Conceptualization: Sang Eun Lee, Sangchul Lee.

Data curation: Hoyoung Ryu, Sang Hun Song, Sangchul Lee.

Formal analysis: Sangchul Lee.

Funding acquisition: Sangchul Lee.

Investigation: Hoyoung Ryu.

Methodology: Sangchul Lee.

Project administration: Hoyoung Ryu, Sangchul Lee.

Resources: Kyoung-Ho Song, Sangchul Lee.

Software: Sangchul Lee.

Supervision: Sang Eun Lee.

Validation: Sangchul Lee.

Visualization: Hoyoung Ryu.

Writing – original draft: Hoyoung Ryu.

Writing – review & editing: Hoyoung Ryu, Sang Hun Song, Sang Eun Lee, Kyoung-Ho Song, Sangchul Lee.

Sangchul Lee orcid: 0000-0003-0844-6843.

References

[1] Cormio L, Cindolo L, Carriero G, et al. Development and internal validation of novel nomograms based on benign prostatic obstruction-related parameters to predict the risk of prostate cancer at first prostate biopsy. Front Oncol 2018;8:438.

[2] Cormio L, Lucarelli G, Carriero G, et al. Absence of bladder outlet obstruction is an independent risk factor for prostate cancer in men undergoing prostate biopsy. Medicine (Baltimore) 2016;95:e2551.

[3] Gopvers TM, Hessels D, Schalken JA, et al. Cost-effectiveness of SelectMDx for prostate cancer in four European countries: a comparative modeling study. Prostate Prostanc Dis 2018.

[4] Ferro M, Muss G, de Cobelli O, et al. Neutrophil, platelets, and eosinophil to lymphocyte ratios predict glasc score upgrading in low-risk prostate cancer patients. Int Urology 2018;10.1159/000494259.

[5] Ferro M, Mirone V, Creta M, et al. Patient selection for active surveillance in the multi-parametric magnetic resonance imaging era: a step forward in a rapidly evolving field. Ann Surg Oncol 2018;10.1245/s10434-018-6746-5.

[6] Lobe S, Carter HB, Berndt SL, et al. Complications after prostate biopsy: data from SEER-Medicare. J Urol 2011;186:1830.

[7] Loe S, van den Heuvel S, Zhu X, et al. Infectious complications and hospital admissions after prostate biopsy in a European randomized trial. Eur Urol 2012;61:1110.

[8] Wagenlehner FM, van Oostrum E, Tenke P, et al. Infective complications after prostate biopsy: outcome of the Global Prevalence Study of Infections in Urology (GPIU) 2010 and 2011, a prospective multinational multicentre prostate biopsy study. Eur Urol 2013;63:521.

[9] Zani EL, Clark OA, Rodrigues Neto NJr. Antibiotic prophylaxis for transrectal prostate biopsy Cochrane Database Syst Rev: 2011; CD006576.

[10] Al-Hasan MN, Lahr BD, Eckel-Passow JE, et al. Antimicrobial resistance trends of Escherichia coli bloodstream isolates: a population-based study, 1998-2007. J Antimicrob Chemother 2009;64:169.

[11] Kehinde EO, Al-Maghrebi M, Sheikh M, et al. Combined ciprofloxacin and amikacin prophylaxis in the prevention of septicaemia after transrectal ultrasound guided biopsy of the prostate. J Urol 2013;189:911.

[12] Ruddick F, Sanders P, Bicknell SG, et al. Sepsis rates after ultrasound-guided prostate biopsy using a bowel preparation protocol in a community hospital. J Ultrasound Med 2011;30:213.

[13] Zaytoun OM, Anil T, Moussa AS, et al. Morbidity of prostate biopsy after simplified versus complex preparation protocols: assessment of risk factors. Urology 2011;77:910.

[14] Huang YC, Ho DR, Wu CF, et al. Modified bowel preparation to reduce infection after prostate biopsy. Chang Gung Med J 2006;29:395.

[15] Akay AF, Akay H, Aflay U, et al. Prevention of pain and infective complications after transrectal prostate biopsy: a prospective study. Int Urol Nephrol 2006;38:45.

[16] Melekos MD. Efficacy of prophylactic antimicrobial regimens in preventing infectious complications after transrectal biopsy of the prostate. Int Urol Nephrol 1990;22:257.

[17] Aghania M, Mirblook F, Shakhia M, et al. Preoperative vaginal preparation with povidone-iodine on post-caesarean infectious morbidity. J Obstet Gynaecol 2011;31:400.

[18] Cieznel AE, Kazy Z, Virgha P. Vaginal treatment with povidone-iodine suppositories during pregnancy. Int J Gynaecol Obstet 2004;84:83.

[19] Pu C, Bai Y, Yuan H, et al. Reducing the risk of infection for transrectal prostate biopsy with povidone-iodine: a systematic reviews and meta-analysis. Int Urol Nephrol 2014;46:1691.

[20] Epstein JL, Eguad L, Amin MB et al. The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: Definition of Grading Patterns and Proposal for a New Grading System. Am J Surg Pathol, doi: 10.1097/PAS.0000000000000530.

[21] Walker JT, Singla N, Roehrborn CG. Reducing infectious complications following transrectal ultrasound-guided prostate biopsy: a systematic review. Rev Urol 2016;18:73.

[22] Abghouzi Z, Margolick J, Goldenberg SL, et al. A prospective randomized trial of povidone-iodine prophylactic cleansing of the rectum before transrectal ultrasound guided prostate biopsy. J Urol 2013;189:1326.

[23] Park DS, Oh JJ, Lee JH, et al. Simple use of the suppository type povidone-iodine can prevent infectious complications in transrectal ultrasound-guided prostate biopsy. Adv Urol 2009;7:50598.

[24] American Urological Association. Best practice policy statement on urologic surgery antimicrobial prophylaxis. 2008. <http://www.auanet.org/content/media/antimicroprop08.pdf> (revised August 2011, updated January 1, 2014) [accessed 5 April, 2014].

[25] Kames J, Yagihara Y, Kume H, et al. Prevalence and characteristics of fecal antimicrobial-resistant Escherichia coli in a cohort of Japanese men undergoing prostate biopsy. Int J Urol 2017;24:235.

[26] Chung HS, Hwang EC, Yu HS, et al. Prevalence of fluoroquinolone-resistant rectal flora in patients undergoing transrectal ultrasound-guided prostate needle biopsy: a prospective multicenter study. Int J Urol 2017.

[27] Lee JK, Lee S, Hong SK, et al. Clinical importance of the antibiotic regimen in transrectal ultrasound-guided biopsy: quinolone versus cephalosporin. BMC Urol 2016;16:51.

[28] Scott S, Harris PN, Williamson DA, et al. The effectiveness of targeted relative to empiric prophylaxis on infectious complications after transrectal ultrasound-guided prostate biopsy: a meta-analysis. World J Urol 2018.

[29] Cassans A, Somani BK, Basarab A, et al. The role of targeted prophylactic antimicrobial therapy before transrectal ultrasonography-guided prostate biopsy in reducing infection rates: a systematic review. BJU Int 2016;117:725.

[30] Yildirim ME, Badem H, Cavis M, et al. The comparison of the influence between two different bowel preparation methods on sepsis after prostate biopsies. Cent European J Urol 2015;68:91.